On CNBC's "Mad Money Lightning Round," Jim Cramer said Navitas Semiconductor Corporation (NASDAQ:NVTS) is "losing a lot of money."
On Tuesday, Navitas Semiconductor announced that Dr. Ranbir Singh, formerly executive vice president at Navitas and the founder and CEO of GeneSiC Semiconductor, has been appointed to the company's board of directors.
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is a "quandary. I've got to tell you, I expected sales to be better," Cramer said. "I do prefer Eli Lilly (NYSE:LLY)."
On Nov. 15, the FDA accepted for review the resubmission of the supplemental biologics license application (sBLA) for Regeneron Pharmaceuticals and Sanofi SA's (NASDAQ:SNY) Dupixent (dupilumab) for patients ages 12 years and older with chronic spontaneous urticaria (CSU) whose disease is not adequately controlled with H1 antihistamine treatment. Wolfe Research analyst Alexandria Hammond initiated coverage on Regeneron Pharmaceuticals with an Outperform rating and announced a price target of $1150.
Cramer said LandBridge Company LLC (NYSE:LB) is a "winner." He recommended holding on to the stock.
On Nov. 7, LandBridge reported quarterly sales of $28.487 million, which missed the analyst consensus estimate of $33.323 million. On Dec. 4, Piper Sandler analyst Mark Lear maintained LandBridge with a Neutral rating and raised the price target from $39 to $79.
Price Action:
- Navitas Semiconductor shares gained 4% to settle at $3.14 on Tuesday.
- Regeneron Pharmaceuticals shares fell 1.7% to close at $749.57.
- LandBridge shares gained 2.8% to close at $74.84 on Tuesday.
- Jim Cramer Prefers FedEx Over This Delivery Giant That 'Screwed Up A Lot Of Holiday Seasons'
Photo: Shutterstock
